DOCSLIB.ORG

Inflammation/Immunology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Inflammation/Immunology The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. www.MedChemExpress.com 1 Inflammation/Immunology Inhibitors & Modulators (+)-Borneol (+)-DHMEQ ((1R,2R,6R)-Dehydroxymethylepoxyquinomicin; (d-Borneol) Cat. No.: HY-N1368A (1R,2R,6R)-DHMEQ) Cat. No.: HY-14645A Bioactivity: (+)-Borneol (d-Borneol) is a natural bicyclic monoterpene used Bioactivity: (+)-DHMEQ is an activator of antioxidant transcription factor for analgesia and anesthesia in traditional Chinese medicine; Nrf2. (+)-DHMEQ is the enantiomer of (-)-DHMEQ. (-)-DHMEQ enhances GABA receptor activity with an EC50 of 248 μM. inhibits NF-kB than its enantiomer (+)-DHMEQ. Purity: 98.0% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 2 mg, 5 mg, 10 mg, 25 mg (-)-Epicatechin (-)-Ketoconazole ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 Cat. No.: HY-B0105B Bioactivity: (-)-Epicatechin inhibits cyclooxygenase-1 ( COX-1) with an Bioactivity: (-)-Ketoconazole is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the levoketoconazole ((2S,4R)-(−)-ketoconazole) and p65 subunit of NF-κB. dextroketoconazole ((2R,4S)-(+)-ketoconazole). Purity: 99.00% Purity: 99.40% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg 10 mg, 50 mg (3R,4S)-Tofacitinib (3S,4R)-Tofacitinib Cat. No.: HY-40354D Cat. No.: HY-40354B Bioactivity: (3R,4S)-Tofacitinib is an enantiomer of Tofacitinib. Bioactivity: (3S,4R)-Tofacitinib is an enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM. Tofacitinib inhibits JAK3 with IC50 of 1 nM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 5 mg (3S,4S)-Tofacitinib (R)-(-)-Ibuprofen Cat. No.: HY-40354C ((R)-Ibuprofen) Cat. No.: HY-78131B Bioactivity: (3S,4S)-Tofacitinib is the S-enantiomer of Tofacitinib. Bioactivity: (R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, inactive Tofacitinib inhibits JAK3 with IC50 of 1 nM. on COX, inhibits NF-κB activation; (R)-(-)-Ibuprofen exhibits anti-inflammatory and antinociceptive effects. Purity: >98% Purity: 98.49% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg 200 mg (R)-BPO-27 (R)-Lansoprazole Cat. No.: HY-19778 (Dexlansoprazole) Cat. No.: HY-13662B Bioactivity: (R)-BPO-27 is a potent CFTR inhibitor with an IC50 of 4 nM. Bioactivity: (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. Target: Proton Pump Lansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been… Purity: 99.56% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg 100 mg, 500 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] (R,R)-Palonosetron Hydrochloride (S)-(+)-Ibuprofen Cat. No.: HY-A0021C ((S)-Ibuprofen) Cat. No.: HY-78131A Bioactivity: (R,R)-Palonosetron Hydrochloride is the active enantiomer of Bioactivity: (S)-(+)-Ibuprofen is the S-enantiomer of Ibuprofen. Ibuprofen Palonosetron. is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively. Purity: 99.61% Purity: 99.97% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 2 mg, 5 mg, 10 mg Size: 1 g, 5 g (S)-(+)-Rolipram (±)-Bisoprolol (hemifumarate) ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (Bisoprolol hemifumarate salt) Cat. No.: HY-B0076 Bioactivity: (S)-(+)-Rolipram is a PDE4-inhibitor and an anti-inflammatory Bioactivity: Bisoprolol is a selective type β1 adrenergic receptor blocker. agent, less potent than its R enantiomer. Purity: 99.85% Purity: 98.41% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg 100 mg, 200 mg, 500 mg 1-O-Acetylbritannilactone 13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide (Inulicin) Cat. No.: HY-N0896 Cat. No.: HY-112077 Bioactivity: 1-O-Acetylbritannilactone is an active compound isolated from Bioactivity: 13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide is a derivative Inula Britannica L. 1-O-Acetylbritannilactone inhibits of Retinoic acid. VEGF-mediated activation of Src and FAK. 1-O-Acetylbritannilactone inhibits LPS-induced PGE2 production and COX-2 expression, and NF-κB activation and… Purity: 99.37% Purity: 98.32% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg 5 mg, 10 mg, 50 mg, 100 mg 14-Deoxy-11,12-didehydroandrographolide 1400W Dihydrochloride (14-dehydro Andrographolide; AP10) Cat. No.: HY-N1490 Cat. No.: HY-18731 Bioactivity: 14-Deoxy-11,12-didehydroandrographolide is an analogue of Bioactivity: 1400W dihydrochloride is a potent and selective inhibitor of Andrographolide that can be isolated from A. paniculata. human inducible NO synthase with Ki values of 7 nM. 14-Deoxy-11,12-didehydroandrographolide inhibits NF-κB activation. Purity: 98.0% Purity: 99.66% Clinical Data: Phase 1 Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg 5 mg, 10 mg, 50 mg, 100 mg 18β-Glycyrrhetinic acid 24-Norursodeoxycholic acid Cat. No.: HY-N0180 (nor-UDCA) Cat. No.: HY-101737 Bioactivity: 18β-Glycyrrhetinic acid is the major bioactive component of Bioactivity: 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened Glycyrrhizae Radix and possesses anti-ulcerative, C 23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and antiproliferative properties. anti-inflammatory and anti-fibrotic properties. Purity: 99.63% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg, 20 mg 500 mg, 5 g www.MedChemExpress.com 3 25-Hydroxycholesterol 3-Deazaadenosine Cat. No.: HY-113134 Cat. No.: HY-W013332 Bioactivity: 25-Hydroxycholesterol is a metabolite of cholesterol that is Bioactivity: 3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine produced and secreted by macrophages in response to Toll-like hydrolase, with a Ki of 3.9 µM; 3-Deazaadenosine has receptor (TLR) activation. 25-hydroxycholesterol is a potent anti-inflammatory, anti-proliferative and anti- HIV activity. (EC 50≈65 nM) and selective suppressor of IgA production by B cells. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: Size: 1 mg, 5 mg, 10 mg 3-Deazaadenosine hydrochloride 4-O-Methyl honokiol Cat. No.: HY-W013332A Cat. No.: HY-U00450 Bioactivity: 3-Deazaadenosine (hydrochloride) is an inhibitor of Bioactivity: 4-O-Methyl honokiol is a natural neolignan isolated from S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM; Magnolia officinalis, acts as a PPARγ agonist, and inhibtis 3-Deazaadenosine has anti-inflammatory, anti-proliferative and NF-κB activity, used for cancer and inflammation research. anti- HIV activity. Purity: 98.06% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 5 mg, 10 mg, 25 mg 1 mg, 5 mg, 10 mg 4-Octyl Itaconate 48740 RP Cat. No.: HY-112675 (RP-55778) Cat. No.: HY-100153 Bioactivity: 4-Octyl Itaconate is a cell-permeable Itaconate derivative. Bioactivity: 48740 RP is a platelet-activating factor ( PAF) antagonist. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Purity: 99.64% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg 50 mg, 100 mg, 200 mg, 500 mg 5-Aminosalicylic Acid 5-Lipoxygenase-In-1 (Mesalamine; 5-ASA; Mesalazine) Cat. No.: HY-15027 Cat. No.: HY-U00308 Bioactivity: 5-Aminosalicylic acid acts as a specific PPARγ agonist and Bioactivity: 5-Lipoxygenase-In-1 is a 5-Lipoxygenase inhibitor extracted also inhibits p21-activated kinase 1 ( PAK1) and NF-κB. from patent EP 331232 A2, table 4, compound example 4.10. Purity: 98.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 mg, 5 mg, 10 mg, 20 mg 10 g 5Z-7-Oxozeaenol 6-Aminochrysene (FR148083; L783279; LL-Z 1640-2) Cat. No.: HY-12686 (6-Chrysenamine) Cat. No.: HY-108315 Bioactivity: 5Z-7-Oxozeaenol is a natural anti-protozoan compound from Bioactivity: 6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as fungal origin, acting as a potent irreversible and selective a chemotherapeutic agent in the treatment of splenomegaly, inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, myeloid leukemia, and breast cancer. respectively. Purity: 99.0% Purity: 95.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10mM x 1mL in DMSO, 25 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] 6-OAU 6-Thioguanine (GTPL5846) Cat.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al

    (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al

    USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • CSID-Abstracts.Pdf

    CSID-Abstracts.Pdf

    The 5th Annual Meeting of Chinese Society of Investigative Dermatology contents Contents E-poster PO-001 Protective properties on oxidative damage of Isorhamnetin and Kaempferol extracted from Vernonia anthelmintica (L.) Willd seeds in human primary melanocytes and keratinocytes ---------------------------------------------------------------------------- HuWen,Wang Hongjuan,Zhang Kunjie,etc 1 PO-002 Effect of IL-17A on NF-κB signaling pathway in human epidermal keratinocytes --------------------------------------------------------------------------------- LiShuang,Hou Shaowei,Feng Jian,etc 2 PO-003 Metabolomics profiling reveals alterations of amino acid and carnitine are metabolic signatures in psoriasisChenChao,Hou Guixue,Zeng Chunwei,etc -------------------------------------------------------------------------- 3 PO-004 Lysophosphatidylcholine promotes the development of psoriasis through metabolic reprogramming ------------------------------------------------------------------------------------ Panpan Liu,Cong Peng,Xiang Chen 4 PO-005 Circular RNA circLOC101928570 suppress systemic lupus erythematosus progression via targeting the miR-150/c-myb axis ---------------------------------------------------- Xingwang Zhao,Longlong Zhang,Junkai Guo,etc 5 PO-006 A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis ----------------------------------------------------------------------------------- Yanghe Liu,Luting Yang,Gang Wang 6 PO-007 Expression of co-inhibitory receptors in psoriasis and correlation
  • Synthesis and Biological Evaluation of Purine and Pyrimidine Based Ligands for the A3 and the P2Y2 Purinergic Receptors

    Synthesis and Biological Evaluation of Purine and Pyrimidine Based Ligands for the A3 and the P2Y2 Purinergic Receptors

    Synthesis and Biological Evaluation of Purine and Pyrimidine Based Ligands for the A3 and the P2Y2 Purinergic Receptors Apr. Liesbet Cosyn Thesis submitted to the Faculty of Pharmaceutical Sciences to obtain the degree of Doctor in Pharmaceutical Sciences Promoter Prof. dr. apr. Serge Van Calenbergh Academic year 2007-2008 TABLE OF CONTENTS 1 INTRODUCTION ................................................................................................. 3 1.1 Purinergic Receptors ................................................................................. 3 1.2 Adenosine Analogues and the Adenosine A3 Receptor ......................... 4 1.2.1 Adenosine................................................................................................. 4 1.2.2 The Adenosine Receptors: G-protein-Coupled Receptors........................ 7 1.2.3 Adenosine Receptor Subtypes and Their Signalling............................... 10 1.2.4 The Adenosine A3 Receptor ................................................................... 12 1.2.4.1 Adenosine A3 Receptor Agonists ................................................. 12 1.2.4.2 Adenosine A3 Receptor Antagonists ............................................ 16 1.2.4.3 Allosteric Modulation.................................................................... 21 1.2.4.4 Molecular Modeling of the Adenosine A3 Receptor...................... 22 1.2.4.5 The Neoceptor concept................................................................ 23 1.2.4.6 Therapeutic Potential of A3AR Agonists......................................
  • USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements

    USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements

    USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements U.S. PHARMACOPEIAL CONVENTION The United States Pharmacopeial Convention Urges Scientific Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements (Rockville, MD – April 16, 2015) – In response to an agreement announced between the New York State Attorney General (NYAG) and GNC Holdings, Inc. (GNC) the United States Pharmacopeial Convention (USP), an independent, science based, standards setting organization and publishers of the United States Pharmacopeia-National Formulary (USP-NF), an official compendia of quality standards for dietary supplements sold in the U.S., issued the following statement: Statement by Gabriel Giancaspro, PhD – Vice President –Foods, Dietary Supplement and Herbal Medicines United States Pharmacopeial Convention (USP) “As a science-based standards-setting organization, the United States Pharmacopeial Convention (USP) has a keen interest in adopting emerging technologies to ensure the test methods and quality standards included in the United States Pharmacopeia-National Formulary (USP-NF) are current and reflect the state of the industry. DNA testing including DNA Barcoding, is just one example of a technology that has been recently added to the USP-NF. As of December 2014, DNA-based identification methods are included in the official USP chapter <563> Identification of Articles of Botanical Origin. However, this method is not yet referenced in a USP-NF monograph (quality standard) for a specific ingredient or product. That is because USP quality standards are specific for each ingredient, product and dosage form and the standards we develop include only those test methods that have been scientifically validated and shown to be fit for purpose.
  • Regulation and Relevance for Chronic Lung Diseases

    Regulation and Relevance for Chronic Lung Diseases

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Purinergic Signalling (2006) 2:399–408 DOI 10.1007/s11302-006-9001-7 ORIGINAL ARTICLE E-NTPDases in human airways: Regulation and relevance for chronic lung diseases Lauranell H. Burch & Maryse Picher Received: 11 January 2005 /Accepted: 21 December 2005 / Published online: 30 May 2006 # Springer Science + Business Media B.V. 2006 Abstract Chronic obstructive lung diseases are char- are characterized by higher rates of nucleotide elimi- acterized by the inability to prevent bacterial infection nation, azide-sensitive E-NTPDase activities and ex- and a gradual loss of lung function caused by recurrent pression. This review integrates the biphasic regulation inflammatory responses. In the past decade, numerous of airway E-NTPDases with the function of purine studies have demonstrated the importance of nucleo- signaling in lung diseases. During acute insults, a tide-mediated bacterial clearance. Their interaction transient reduction in E-NTPDase activities may be with P2 receptors on airway epithelia provides a rapid beneficial to stimulate ATP-mediated bacterial clear- Fon-and-off_ signal stimulating mucus secretion, cilia ance. In chronic lung diseases, elevating E-NTPDase beating activity and surface hydration. On the other activities may represent an attempt to prevent P2 hand, abnormally high ATP levels resulting from receptor desensitization and nucleotide-mediated lung damaged epithelia and bacterial lysis may cause lung damage. edema and exacerbate inflammatory responses. Air- way ATP concentrations are regulated by ecto nucle- Keywords apyrase . bacterial clearance . CD39 . oside triphosphate diphosphohydrolases (E-NTPDases) chronic obstructive lung diseases .
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
  • Etats Rapides

    Etats Rapides

    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate